Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-na ïve metastatic castration-resistant prostate cancer in Japan
ConclusionsResults modeled herein suggest that the enzalutamide-first sequencing is more cost-effective than the abiraterone-first sequencing, but less cost-effective than docetaxel-first sequencing for chemotherapy-na ïve patients with metastatic castration-resistant prostate cancer.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Healthcare Costs | Japan Health | Prostate Cancer | Taxotere